In mouse xenograft models, siRSL1D1 treatment produced an excellent therapeutic efficacy in suppressing the growth of HCT116p53+/+ tumors (Fig. 8), demonstrating that downregulation of RSL1D1 is a highly efficient therapeutic strategy for treating CRC. This evidence concerns the gene RSL1D1 and colorectal carcinoma.